Cardiopulmonary Disease Diagnostics and Treatment Market Size was prized at USD 2.34 Billion in 2023. The cardiopulmonary disease diagnostics and treatment market industry is projected to grow from USD 2.49 Billion in 2024 to USD 3.97 Billion by 2032, illustrating a compound annual growth rate (CAGR) of 5.96% from 2024 to 2032. The growing geriatric population, the rise in the prevalence of cardiovascular illnesses, poor food & sedentary lifestyle are the key market drivers strengthening the market growth. The market for cardiopulmonary disease diagnostics and treatment is growing due to technological developments in treatments, devices, and improved treatment methods.
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
In March 2024, Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO), an AI-driven precision cardiovascular medicine company, announced today that the Company’s clinical blood tests, Epi+Gen CHD and PrecisionCHD, are now available at Family Medicine Specialists’ (FMS) newest clinical location at the Walmart Supercenter in Round Lake Beach, Illinois. FMS is a leading primary care and risk-bearing provider in Northern Illinois. In December 2023, it launched the ongoing Heart Attack Prevention Initiative for at least 1,200 of its BlueCross BlueShield and other health plan patients. With this launch into a retail healthcare setting, it allows access to both existing and new patients within that area.
Eighteen million and five hundred thousand Euros were invested in Idoven in June 2022 to build its Artificial Intelligence (AI) platform for cardiac diagnostics. The intention of the platform is to help detect cardiac defects and arrhythmias early.
Abbott acquired Cardiovascular Systems Inc. in February 2023, which will give Abbott a competitive edge in terms of cardiac diagnosis with an unparalleled set of complementary products offered by CSI’s flagship atherectomy system that treats vascular diseases.
In November 8, 2021, Philips declared that it had entered into an agreement to buy Cardiologs after completing several stages of negotiations with this French medical technology firm that is rebuilding cardiology using artificial intelligence (AI) technology. In addition to Philips’ cardiac monitoring and diagnostics offering, including innovative software technologies and ECG analysis as well as reporting services, Cardiologs also strengthens the Company’s portfolio by providing such solutions through its innovative software technology, EKG analysis, and reporting service.
Cleerly launched power imaging AI-based technology at Weill Cornell Medicine and New York-Presbyterian Hospital, supported by an investment worth $43m on June 21, 2021. Unlike traditional markers such as blood cholesterol levels used to track heart health, this device strives towards a more holistic view of these vital organs, which can be indicative when there is a high potential risk for attack.
This year, during their annual meeting called European Society of Cardiology (ESC), the Aug. 25-28 Amsterdam symposium was held by Siemens Healthineers on the Acuson Origin1 cardiovascular ultrasound system with new robust artificial intelligence (AI) features. To enhance patient outcomes and facilitate minimally invasive treatments done by cardiologists with great success, Acuson Origin takes care of everything from diagnosis to intervention aspects, including diagnostic, structural heart, electrophysiological, and pediatric procedures.
Market CAGR for cardiopulmonary disease diagnostics and treatment is driven by the growing prevalence of cardiovascular diseases. The increasing prevalence of chronic cardiovascular illnesses worldwide is a major driver of cardiopulmonary disease diagnostics and treatment in the market. According to World Health Organisation, cardiovascular disease is the leading cause of mortality worldwide. ly, 17.9 million people die from cardiovascular disorders each year. High salt intake in the diet, increased tobacco use, increased smoking prevalence, and increased alcohol use are the main contributors to cardiovascular illnesses. By catching cardiovascular disorders early, they can be efficiently treated. Therefore, the market for cardiopulmonary disease diagnostics and treatment is predicted to rise due to the increasing demand for early identification of cardiovascular disorders.
The rising number of persons with diabetes and obesity drives the market for cardiopulmonary disease diagnostics and treatment. Obesity is linked to risk factors like high blood pressure and high cholesterol, and diabetes increases the risk of cardiovascular illnesses. For instance, as per a study by American Heart Association (AMA), CVD cases will increase to 22.2 million by 2030. Another study by the American Medical Association (AMA) in the U.S. found that 26 million people have had diabetes diagnosed and that an additional 9 million people have the condition but have not yet received a diagnosis. Thus, driving the cardiopulmonary disease diagnostics and treatment market revenue.
The cardiopulmonary disease diagnostics and treatment market segmentation, based on disease type, include cardiovascular and respiratory diseases. The cardiovascular segment dominated the market, accounting for 50.8% of market revenue (1.1 Billion). The main sector drivers are rapid technical development, increased prevalence of cardiovascular illnesses worldwide, and rising demand for minimally invasive procedures. The increasing prevalence of heart illnesses such as cardiomyopathy and stroke is the main contributor to cardiovascular-related mortality. Furthermore, the respiratory diseases sector saw considerable growth. Air pollution is a serious issue, and COPD prevalence is rising ly, especially in developing nations with high smoking rates. The aging population, urbanization, and lifestyle modifications are a few causes of the rise in respiratory disease prevalence. People are more prone to respiratory diseases as they get older.
Figure 1 Cardiopulmonary Disease Diagnostics and Treatment Market, by Disease Type, 2023 & 2032 (USD Billion)
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
The cardiopulmonary disease diagnostics and treatment market segmentation, based on type, includes diagnosis-electrocardiogram and treatment-medication. In 2022, the diagnosis-electrocardiograms segment dominated the market. Due to the growing usage of ECG diagnostic techniques in diagnosing cardiac illnesses such as arrhythmia, congenital heart anomalies, and coronary occlusion, the Electrocardiogram (ECG or EKG) segment accounted for a sizably substantial revenue share.
September 2020 AliveCor, announced its entry into the Indian market with the breakthrough introduction of KardiaMobile 6L, the most clinically-validated personal ECG device. Because of the country's access issues to excellent healthcare and COVID-related infection fears, the portable and technology-enabled ECG gadget will assist in providing inexpensive and easy heart care to over 260 million heart patients and those at risk without requiring them to visit a hospital.
Additionally, in 2022, the treatment-medication segment witnessed the fastest growth rate. The sector for cardiovascular drugs is projected to grow due to the availability of medication classes used to treat cardiovascular indications such as hyperlipidemia and hypertension.
The cardiopulmonary disease diagnostics and treatment market segmentation, based on end-user, includes diagnostic centers and hospitals. Over the projection period in 2022, the hospital segment's revenue share was higher. Greater utilization of cutting-edge imaging and diagnostic technology for workflow automation and accurate cardiac disease identification is fueling the segment's revenue growth. Because laboratory testing is more sophisticated and fully integrated with the technology required to ensure that results are accurate, analyzed, validated, and recorded, the diagnostic center's segment is predicted to hold the largest market share in 2022 and continue to dominate during the forecast period.
By region, the study provides market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American cardiopulmonary disease diagnostics and treatment market area will dominate this market due to the high incidence of cardiovascular diseases, the rapid adoption of minimally invasive procedures, the existence of reimbursements, the growing geriatric population, and the high demand for continuous and home-based monitoring. According to the CDC's most recent statistics, released in October 2022, a heart attack happens in the US every 40 seconds, and over 805,000 people experience one yearly.
Further, the major countries studied in the market report are US, Canada, France, German, Italy, UK, Spain, Japan, China, Australia, India, South Korea, and Brazil.
Figure 2 CARDIOPULMONARY DISEASE DIAGNOSTICS AND TREATMENT MARKET SHARE BY REGION 2022 (USD Billion)
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe’s cardiopulmonary disease diagnostics and treatment market accounts for the second-largest market share due, among other things, to a constant increase in the number of patients with CAD and peripheral artery disorders. According to figures made available by the European Union on March 21, 2022, heart attacks were a significant cause of fatalities in the EU. Additionally, technical developments enable portable characteristics in testing equipment, supporting the expansion of the market's revenue. Further, the German cardiopulmonary disease diagnostics and treatment market held the major market share, and the UK cardiopulmonary disease diagnostics and treatment market was the rapidly growing market in the European region.
The Asia-Pacific Cardiopulmonary Disease Diagnostics and Treatment Market is anticipated to grow quickly from 2024 to 2032. It is due to a high prevalence of heart illnesses in some areas and a sizable patient base needing treatment in nations like China and India. According to a report released by BioSpectrum on June 23, 2022, the number of heart attacks among people under 50 has dramatically grown in China over the past ten years. All age groups, including those under 50, have shown a rise in the age-specific incidence rate of heart attacks per 100,000 persons. Moreover, China’s cardiopulmonary disease diagnostics and treatment market held the major market share, and the Indian cardiopulmonary disease diagnostics and treatment market was the rapidly growing market in the Asia-Pacific region.
Cardiopulmonary Disease Diagnostics and Treatment Key Market Players & Competitive Insights
Leading market players are largely investing in research and development to expand their product lines, which will help the cardiopulmonary disease diagnostics and treatment market grow even more. The launch of new products, larger-scale mergers and acquisitions, contractual agreements, and collaboration with other organizations are significant market developments in which market participants engage to increase their presence. The cardiopulmonary disease diagnostics and treatment industry must provide affordable products to expand and thrive in a more competitive and challenging market environment.
One of the major business strategies manufacturers use in the cardiopulmonary disease diagnostics and treatment industry to increase market sector and benefits customers is local manufacturing to lower operational costs. In recent years, the cardiopulmonary disease diagnostics and treatment industry has stipulated some of the most important medicinal benefits. Major players in the cardiopulmonary disease diagnostics and treatment industry, including Cosmed Medical, Cardinal Health, GE Healthcare, Schiller AG, Koninklijke Philips N.V., and others, are funding operations for research and development to boost market demand.
Medtronic plc is a medical device firm based in the United States. The operational and executive headquarters of the corporation are in Minneapolis, Minnesota, and the legal headquarters are in Ireland. Medtronic PLC creates medical products that are both therapeutic and diagnostic. Products for bradycardia pacing, tachyarrhythmia management, atrial fibrillation management, heart failure management, heart valve replacement, malignant and non-malignant pain, and movement disorders are among the company's mainstays. In October 2022, Medtronic plc received FDA approval for expanded labeling of a cardiac lead that taps into the heart's natural electrical system, providing needed therapy while avoiding complications associated with traditional pacing methods, such as cardiomyopathy. Medtronic was the first and only firm to approve conduction system pacing therapy.
GSK plc, formerly GlaxoSmithKline plc, is a multinational pharmaceutical and biotechnology corporation based in London, England. GSK is one of the major pharmaceutical firms in terms of total sales. The company has clout in various therapeutic areas, including respiratory, cancer, antiviral drugs, and vaccines. GSK employs joint ventures to develop scale in some industries, such as HIV. In April 2022, GlaxoSmithKline Pharmaceuticals Limited introduced Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol), the first single-inhaler triple treatment (SITT) in India for Chronic Obstructive Pulmonary Disease (COPD) patients on a once-daily basis. Drugs Controller General of India approved the medicine as a maintenance treatment to prevent and relieve Chronic Obstructive Pulmonary Disease symptoms in patients aged 18 and above.
Key Companies in the cardiopulmonary disease diagnostics and treatment market include
Cardiopulmonary Disease Diagnostics and Treatment Industry Developments
February 2021 Remo Care Solutions has created a new AI-based remote monitoring gadget for cardiac patients that analyses the patient's cardiovascular status in real-time. Patients can easily use this lightweight wireless device in their rooms or ICU. During a Covid pandemic, the technology allows patients to avoid physically seeing doctors, allowing doctors to diagnose disease through remote monitoring.
April 2021 Phoenix Cardiac Devices has received regulatory CE mark certification for their BACE (basal annuloplasty of the cardiac externally) device, which will be used to treat functional mitral regurgitation. Compared to other devices that treat mitral regurgitation by replacing or repairing the mitral valve, the BACE device is unique.
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 2.34 Billion |
| Market Size 2024 | USD 2.49 Billion |
| Market Size 2032 | USD 3.97 Billion |
| Compound Annual Growth Rate (CAGR) | 5.96% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Market Competitive Landscape, Growth Factors, Revenue Forecast, and Trends |
| Segments Covered | Disease Type, Type, and End-user |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | US, Canada, France, German, Italy, UK, Spain, Japan, China, Australia, India, South Korea, and Brazil. |
| Key Companies Profiled | Cosmed Medical, Cardinal Health, GE Healthcare, Schiller AG, and Koninklijke Philips N.V. |
| Key Market Opportunities | Rapid technological advancements |
| Key Market Dynamics | Increasing prevalence of coronary artery diseases |
Cardiopulmonary Disease Diagnostics Treatment Market Highlights:
Frequently Asked Questions (FAQ) :
The market size of the cardiopulmonary disease diagnostics and treatment market was prized at USD 2.34 Billion in 2023.
From 2024 to 2032, the anticipated CAGR for the market is 5.96%.
The major portion of the market was accounted for by North America.
The notable players in the market are Cosmed Medical, Cardinal Health, GE Healthcare, Schiller AG, and Koninklijke Philips N.V.
The cardiovascular disease type dominated the market in 2023.
The echocardiogram sector had the largest share of the market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
